State of Tennessee Treasury Department continued to hold its stake in Haemonetics Corp. (NYSE:HAE) during the third quarter, Holdings Channel reports. The firm owned 41,170 shares of the company’s stock at the end of the third quarter. State of Tennessee Treasury Department’s holdings in Haemonetics Corp. were worth $1,491,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of HAE. Vanguard Group Inc. raised its stake in Haemonetics Corp. by 1.8% in the second quarter. Vanguard Group Inc. now owns 4,037,091 shares of the company’s stock worth $117,035,000 after buying an additional 70,299 shares during the period. BlackRock Fund Advisors raised its stake in Haemonetics Corp. by 8.6% in the third quarter. BlackRock Fund Advisors now owns 3,616,662 shares of the company’s stock worth $130,959,000 after buying an additional 284,894 shares during the period. Victory Capital Management Inc. raised its stake in Haemonetics Corp. by 34.0% in the third quarter. Victory Capital Management Inc. now owns 1,963,684 shares of the company’s stock worth $71,105,000 after buying an additional 497,834 shares during the period. Dimensional Fund Advisors LP raised its stake in Haemonetics Corp. by 14.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,804,922 shares of the company’s stock worth $52,324,000 after buying an additional 228,856 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its stake in Haemonetics Corp. by 1.0% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,284,789 shares of the company’s stock worth $46,522,000 after buying an additional 13,135 shares during the period. Institutional investors and hedge funds own 99.30% of the company’s stock.
Shares of Haemonetics Corp. (NYSE:HAE) traded up 1.27% on Thursday, hitting $40.02. The stock had a trading volume of 715,525 shares. The stock’s market cap is $2.07 billion. Haemonetics Corp. has a 1-year low of $25.98 and a 1-year high of $41.41. The firm’s 50-day moving average is $40.10 and its 200 day moving average is $36.36.
Haemonetics Corp. (NYSE:HAE) last released its quarterly earnings data on Monday, November 7th. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.11. Haemonetics Corp. had a positive return on equity of 10.99% and a negative net margin of 6.48%. The company had revenue of $220.30 million for the quarter, compared to analyst estimates of $210.72 million. During the same period in the prior year, the company posted $0.44 EPS. The company’s revenue was up .3% compared to the same quarter last year. Equities analysts forecast that Haemonetics Corp. will post $1.50 EPS for the current year.
A number of equities research analysts have recently issued reports on HAE shares. BTIG Research reiterated a “neutral” rating on shares of Haemonetics Corp. in a research note on Monday, November 7th. Benchmark Co. increased their target price on Haemonetics Corp. from $32.00 to $34.00 and gave the company a “hold” rating in a research note on Monday, November 7th. Zacks Investment Research lowered Haemonetics Corp. from a “buy” rating to a “hold” rating in a research note on Thursday, January 5th. Barrington Research upgraded Haemonetics Corp. from a “market perform” rating to an “outperform” rating and set a $41.00 price objective for the company in a research note on Tuesday, November 8th. Finally, Off Wall Street assumed coverage on Haemonetics Corp. in a research note on Friday, October 14th. They set a “sell” rating and a $24.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company. Haemonetics Corp. presently has a consensus rating of “Hold” and a consensus price target of $34.57.
In other news, Director Ronald G. Gelbman sold 5,683 shares of the company’s stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $40.30, for a total value of $229,024.90. Following the sale, the director now directly owns 49,688 shares in the company, valued at approximately $2,002,426.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.50% of the company’s stock.
About Haemonetics Corp.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corp. (NYSE:HAE).